Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPD | P32754 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041564 | 0.87 | PTGDR2 (0.49) | AKR1B1AKR1A1PTGDR2DGAT1 | |
| SCHEMBL5040978 | 0.83 | CHRNA7 (0.45) | — | |
| SCHEMBL27686599 | 0.82 | NAAA (0.48) | AKR1B1PDPK1MEN1KMT2AHPD | |
| SCHEMBL3172071 | 0.81 | PTGDR2 (0.48) | AKR1B1PTGDR2MEN1KMT2A | |
| SCHEMBL2347875 | 0.78 | POLB (0.54) | — | |
| SCHEMBL5042108 | 0.78 | IDO1 (0.56) | PTGDR2 | |
| SCHEMBL29574729 | 0.78 | AKR1B1 (0.52) | AKR1B1AKR1A1PDPK1MEN1KMT2A | |
| SCHEMBL5835 | 0.78 | AKR1B1 (0.52) | AKR1B1AKR1A1PDPK1MEN1KMT2A | |
| SCHEMBL30280535 | 0.77 | PKM (0.58) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL8174893 | 0.77 | PTGDR2 (0.49) | AKR1B1AKR1A1PTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | AKR1B1 2931/4885AKR1A1 1868/4885PTGDR2 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.